Cuts to Medicaid and other federal health programs proposed in President Donald Trump’s budget plan would rapidly push more than 300 financially struggling rural hospitals toward a fiscal cliff, according to researchers who track the facilities’ finances. The hospitals would be at a disproportionate risk of closure, service reductions, or ending inpatient care, according to…
Innovations in biomarker science, particularly in cerebrospinal fluid (CSF) and blood, are expanding Alzheimer’s testing beyond specialty care. The post The Key Biomarkers Changing How and When We Diagnose Alzheimer’s Disease appeared first on MedCity News.
Health tech companies made several major funding announcements in September. Here is a list of some of the biggest funding rounds. The post 4 Notable Health Tech Funding Announcements in September appeared first on MedCity News.
Legislation passed by the Energy and Commerce Committee could increase the number of people without health insurance by 8.6 million, due largely to changes to Medicaid and the ACA. Combining the provisions with the effect of the expected expiration of the ACA’s enhanced premium tax credits, CBO expects 13.7 million more people will be uninsured…
Joey Ballard is an internal medicine resident at the University of Illinois-Chicago. He wrote to “An Arm and a Leg” about a resolution the American Medical Association recently adopted calling on hospitals to do more to make sure patients who qualify for charity care get it. And that legislators and regulators make sure that’s happening….
There is no excerpt because this is a protected post.
Professor Rick Dakan (Ringling College of Art and Design) and Professor Joseph Feller (University College Cork) developed the 4D Framework for AI Fluency. What is it? Delegation: Deciding on what work should be done by humans, what work should be done by AI, and how to distribute tasks between them. Includes understanding your goals, AI capabilities,…
Advanced computing infrastructure will initially support foundation model development for pathomics, drug discovery and precision medicine
M&A activity is going beyond big pharma acquisitions with Supernus Pharmaceuticals and Indivior Pharmaceuticals reaching a stock deal that the companies call a merger of equals. The combined company’s portfolio will have 11 commercialized products in addiction, attention-deficit hyperactivity disorder, depression, and Parkinson’s disease. The post Supernus and Indivior to Merge, Forming a New CNS-Focused…
Drug development isn’t limited by the amount of data we collect, but by our ability to preserve the context, meaning and relationships that transform data into evidence. The post AI in Drug Development is Not a Data Problem — It’s An Evidence Problem appeared first on MedCity News.